ReviewCurrent psychiatry reports2017
Genetics of Schizophrenia: Ready to Translate?
Review in Current psychiatry reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Parental mental disorders in patients with comorbid schizophrenia and obsessive-compulsive disorder: a nationwide family-link study.European child & adolescent psychiatry · 2024Article
- The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable.Biological psychiatry global open science · 2024Article
- Convergent and divergent genes expression profiles associated with brain-wide functional connectome dysfunction in deficit and non-deficit schizophrenia.Translational psychiatry · 2024Article
- Association of dopamine-based genetic risk score with dynamic low-frequency fluctuations in first-episode drug-naïve schizophrenia.Brain imaging and behavior · 2023Article
- Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combiningiScience · 2022Article
- Review
- A multifactorial model for the etiology of neuropsychiatric disorders: the role of advanced paternal age.Pediatric research · 2022Review
- Expression Analysis of Ermin and Listerin E3 Ubiquitin Protein Ligase 1 Genes in the Periphery of Patients with Schizophrenia.Journal of molecular neuroscience : MN · 2022Article
- Identification of a Rare Novel KMT2C Mutation That Presents with Schizophrenia in a Multiplex Family.Journal of personalized medicine · 2021Article
- Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.Pharmacological reports : PR · 2021Review
- Migratory cortical interneuron-specific transcriptome abnormalities in schizophrenia.Journal of psychiatric research · 2021Article
- Neurexins in autism and schizophrenia-a review of patient mutations, mouse models and potential future directions.Molecular psychiatry · 2021Review
- Chromosomal Microarray Analysis as First-Tier Genetic Test for Schizophrenia.Frontiers in genetics · 2021Article
- Editorial: Antipsychotics of New Generation: Where Are We now?Frontiers in pharmacology · 2021Article
- Neuroimmune Mechanisms and Sex/Gender-Dependent Effects in the Pathophysiology of Mental Disorders.The Journal of pharmacology and experimental therapeutics · 2020Review
- Observational
- Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer.G3 (Bethesda, Md.) · 2020Article
- Review
- Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review.Public health genomics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis is an era where we have significantly advanced the understanding of the genetic architecture of schizophrenia. In this review, we consider how this knowledge may translate into advances that will improve patient care. RECENT
findingsLarge-scale genome-wide association studies (GWAS) have identified more than a hundred loci each making a small contribution to illness risk. Meta-analysis of copy number variants (CNVs) in the Psychiatric Genomics Consortium (PGC) dataset has confirmed that some variants have a moderate or large impact on risk, although these are rare in the population. Genome sequencing advances allow a much more comprehensive evaluation of genomic variation. We describe the key findings from whole exome studies to date. These studies are happening against a backdrop of growing understanding of the regulation and expression of genes and better functional tools to investigate molecular mechanisms in model systems. We provide an overview of how recent approaches in schizophrenia genetics are converging and consider how they could impact on diagnostics, the development of personalized medicine, and drug discovery.
Indexed as
Identifiers
28741255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.